{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"196"}],"units":"Participants"}],"description":"The number of participants with grade 4 neutropenia for chemotherapy cycle 1. Grade 4 (severe) neutropenia was defined as ANC \\<0.5 × 109/L within the first 12 days of chemotherapy.","groups":[{"description":"F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.\n\nF-627: single dose pre-filled syringe","id":"OG000","title":"F-627"},{"description":"6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles\n\nNeulasta: single dose pre-filled syringe","id":"OG001","title":"Neulasta"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT (Intent-to-Treat) population","reportingStatus":"POSTED","timeFrame":"The first of 4, 21-day chemotherapy cycles (average 3 weeks)","title":"The Number of Participants With Grade 4 Neutropenia for Chemotherapy Cycle 1","type":"SECONDARY","unitOfMeasure":"Participants"}